These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30287928)

  • 1. Nrf2 mediates the resistance of human A549 and HepG2 cancer cells to boningmycin, a new antitumor antibiotic, in vitro through regulation of glutathione levels.
    Zhang HX; Chen Y; Xu R; He QY
    Acta Pharmacol Sin; 2018 Oct; 39(10):1661-1669. PubMed ID: 30287928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
    Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
    Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-elemene reverses the drug resistance of lung cancer A549/DDP cells via the mitochondrial apoptosis pathway.
    Yao CC; Tu YR; Jiang J; Ye SF; Du HX; Zhang Y
    Oncol Rep; 2014 May; 31(5):2131-8. PubMed ID: 24627125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs.
    Tang X; Wang H; Fan L; Wu X; Xin A; Ren H; Wang XJ
    Free Radic Biol Med; 2011 Jun; 50(11):1599-609. PubMed ID: 21402146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway.
    Wu S; Zhang T; Du J
    Drug Des Devel Ther; 2016; 10():3471-3481. PubMed ID: 27822011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of the Glutathione, Thioredoxin, and Nrf2 Antioxidant Systems in Head and Neck Cancer.
    Roh JL; Jang H; Kim EH; Shin D
    Antioxid Redox Signal; 2017 Jul; 27(2):106-114. PubMed ID: 27733046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptotanshinone Reverses Cisplatin Resistance of Human Lung Carcinoma A549 Cells through Down-Regulating Nrf2 Pathway.
    Xia C; Bai X; Hou X; Gou X; Wang Y; Zeng H; Huang M; Jin J
    Cell Physiol Biochem; 2015; 37(2):816-24. PubMed ID: 26356271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
    Chian S; Li YY; Wang XJ; Tang XW
    Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclometalated Ru(II)-isoquinoline complexes overcome cisplatin resistance of A549/DDP cells by downregulation of Nrf2 via Akt/GSK-3β/Fyn pathway.
    Chen L; Wang J; Cai X; Chen S; Zhang J; Li B; Chen W; Guo X; Luo H; Chen J
    Bioorg Chem; 2022 Feb; 119():105516. PubMed ID: 34856444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer.
    Homma S; Ishii Y; Morishima Y; Yamadori T; Matsuno Y; Haraguchi N; Kikuchi N; Satoh H; Sakamoto T; Hizawa N; Itoh K; Yamamoto M
    Clin Cancer Res; 2009 May; 15(10):3423-32. PubMed ID: 19417020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent antitumor actions of the new antibiotic boningmycin through induction of apoptosis and cellular senescence.
    Gao N; Shang B; Zhang X; Shen C; Xu R; Xu H; Chen R; He Q
    Anticancer Drugs; 2011 Feb; 22(2):166-75. PubMed ID: 20948431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance of neuroblastoma GI-ME-N cell line to glutathione depletion involves Nrf2 and heme oxygenase-1.
    Furfaro AL; Macay JR; Marengo B; Nitti M; Parodi A; Fenoglio D; Marinari UM; Pronzato MA; Domenicotti C; Traverso N
    Free Radic Biol Med; 2012 Jan; 52(2):488-96. PubMed ID: 22142473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nrf2 mediates the protective effects of homocysteine by increasing the levels of GSH content in HepG2 cells.
    Zhang B; Dong JL; Chen YL; Liu Y; Huang SS; Zhong XL; Cheng YH; Wang ZG
    Mol Med Rep; 2017 Jul; 16(1):597-602. PubMed ID: 28560453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of stable inhibition of NRF2 on doxorubicin sensitivity in human ovarian carcinoma OV90 cells.
    Manandhar S; Lee S; Kwak MK
    Arch Pharm Res; 2010 May; 33(5):717-26. PubMed ID: 20512470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo.
    Chian S; Thapa R; Chi Z; Wang XJ; Tang X
    Biochem Biophys Res Commun; 2014 May; 447(4):602-8. PubMed ID: 24747074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming Cancer Cell Drug Resistance by a Folic Acid Targeted Polymeric Conjugate of Buthionine Sulfoximine.
    Cilurzo F; Cristiano MC; Da Pian M; Cianflone E; Quintieri L; Paolino D; Pasut G
    Anticancer Agents Med Chem; 2019; 19(12):1513-1522. PubMed ID: 31241440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive response to GSH depletion and resistance to L-buthionine-(S,R)-sulfoximine: involvement of Nrf2 activation.
    Lee HR; Cho JM; Shin DH; Yong CS; Choi HG; Wakabayashi N; Kwak MK
    Mol Cell Biochem; 2008 Nov; 318(1-2):23-31. PubMed ID: 18587629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alkylating Agent-Induced NRF2 Blocks Endoplasmic Reticulum Stress-Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis.
    Zanotto-Filho A; Masamsetti VP; Loranc E; Tonapi SS; Gorthi A; Bernard X; Gonçalves RM; Moreira JC; Chen Y; Bishop AJ
    Mol Cancer Ther; 2016 Dec; 15(12):3000-3014. PubMed ID: 27638861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Characteristics of boningmycin induced cellular senescence of human tumor cells].
    Zhang XM; Gao N; Chen RX; Xu HZ; He QY
    Yao Xue Xue Bao; 2010 May; 45(5):589-94. PubMed ID: 20931760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
    Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
    Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.